STOCK TITAN
  1. Home
  2. News
  3. OSUR

Orasure Technologies Inc. - OSUR STOCK NEWS

Welcome to our dedicated news page for Orasure Technologies (Ticker: OSUR), a resource for investors and traders seeking the latest updates and insights on Orasure Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Orasure Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Orasure Technologies's position in the market.

News
OraSure to Announce First Quarter 2024 Financial Results and Host Earnings Call on May 8th
Rhea-AI Summary
OraSure Technologies, Inc. (NASDAQ: OSUR) will announce its first-quarter 2024 financial results and host an earnings call on May 8th, 2024. The conference call will cover financial results and business developments, with a webcast available on OraSure's investor relations page. Participants can pre-register for the live call via a provided link.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
earnings
-
News
NOWDiagnostics Welcomes Dr. Stephen S. Tang as Chairman of the Board
Rhea-AI Summary
NOWDiagnostics (NOWDx) appoints Dr. Stephen S. Tang, former head of OraSure Technologies, as the chairman of the board. Dr. Tang brings extensive experience in the medical diagnostic industry, having led OraSure Technologies to significant growth and product development during his tenure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.76%
Tags
none
-
News
OraSure Reports Q4 ‘23 Revenue of $75.9 Million
Rhea-AI Summary
OraSure Technologies, Inc. (OSUR) reported Q4 GAAP EPS of $0.27 and Q4 Non-GAAP EPS of $0.22. The company's cash balance grew to $290.4 million as of December 31, 2023. OraSure entered the U.S. Syphilis testing market through a strategic distribution agreement with Diagnostics Direct. The company highlighted progress in operational cash flow and margin expansion, aiming for break-even in cash flow from operations for the core business by the end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.96%
Tags
none
News
OraSure to Announce Fourth Quarter 2023 Financial Results and Host Earnings Call on February 27th
Rhea-AI Summary
OraSure Technologies, Inc. (OSUR) will hold its earnings conference call for Q4 2023 financial results and business updates on Feb. 27, 2024, at 5 p.m. ET. The webcast will be available on the company's investor relations page. Participants can register in advance for access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
earnings
-
News
OraSure Technologies, Inc. Secures Strategic Distribution Rights and Invests in Sapphiros, a Next-Generation Consumer Diagnostics Company 
Rhea-AI Summary
OraSure Technologies, Inc. (NASDAQ: OSUR) expands innovation pipeline and revenue growth through strategic partnership with Sapphiros, a consumer diagnostics portfolio company. OraSure leads Series B financing and secures exclusive distribution rights to key products in Sapphiros' development pipeline, aligning with OraSure's areas of expertise. Initial product distribution expected in 2024, with accelerated revenue growth anticipated beginning in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
none
-
News
OraSure to Participate in Upcoming Investor Conferences
Rhea-AI Summary
OraSure Technologies, Inc. (NASDAQ: OSUR) announces participation in investor conferences. Live webcasts and replays available on the company's investor relations page.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.98%
Tags
conferences
News
OraSure Reports Q3 ‘23 Revenue of $89.2 Million; Core Revenue Grows 7% Year-over-Year
Rhea-AI Summary
OraSure Technologies, Inc. (NASDAQ: OSUR) Announces Q3 GAAP EPS of $0.15 and Q3 Non-GAAP EPS of $0.27, Grows Cash Balance to $224.9M, Reports 7% Core Revenue Growth, and Provides Financial Guidance
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
none
-
News
OraSure to Announce Third Quarter 2023 Financial Results and Host Earnings Call on November 7th
Rhea-AI Summary
OraSure Technologies, Inc. has scheduled its regular earnings conference call for November 7, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.38%
Tags
earnings
-
News
OraSure Reports Q2 ‘23 Revenue of $85.4 Million; Core Revenue Grows 3% Year-over-Year
Rhea-AI Summary
OraSure Technologies, Inc. announces Q2 2023 financial results, with InteliSwab® test revenue of $47.5 million, a 10% YoY increase. Q2 core revenue grew 4% sequentially and 3% YoY. Cash balance increased to $185.9 million. InteliSwab® orders expected to generate at least $70 million in revenue in H2 2023. On track to achieve operating cash flow breakeven on core business by end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.29%
Tags
none
News
OraSure to Announce Second Quarter 2023 Financial Results and Host Earnings Call on August 3rd
Rhea-AI Summary
OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call for 5:00 pm ET on Thursday, August 3, 2023. A webcast of the conference call will be available on OraSure's website. The webcast will be archived for approximately 90 days. To participate in the live conference call, pre-registration is required.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
earnings
Stock OSUR logo
Orasure Technologies Inc.

Nasdaq:OSUR

OSUR Rankings

#3146 Ranked by Market Cap
#969 Ranked by Stock Gains
N/A Ranked by Dividends

OSUR Stock Data

422.34M
67.02M
3.66%
92.9%
3.87%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Bethlehem

About OSUR

based in bethlehem, pennsylvania, orasure technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. these products include tests for the detection of antibodies to the hiv virus, including the oraquick® in-home hiv test, oraquick advance® rapid hiv-1/2 antibody test and the orasure® hiv-1 oral specimen collection device, a test for antibodies to the hcv virus, the oraquick® hcv rapid antibody test, and oral fluid testing solutions for drugs of abuse testing, including intercept® oral fluid drug testing system and q.e.d.® saliva alcohol test. orasure also manufactures and sells several leading cryosurgical products. these include: histofreezer®, a product for the cryosurgical removal of common and plantar warts and several other benign skin lesions, sold to the professional or physician office market, as well as an over-the-counter product fo